Third Rock Continues To Attract Investors, Closes $516M Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.
You may also be interested in...
Venture Investing In Biotech Still Strong, Says E&Y Report
The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.
Cydan Hopes To Accelerate Rare Disease Drug Development With $16M Raise
The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.
Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.